Cargando…
Competitive rational inhibitor design to 4-maleylaceto-acetate isomerase
Tyrosinemia type I is the result of genetic disorder in fomaryl acetoacetase gene that leads to 4-fumaryl acetoacetate accumulation. The current treatment for tyrosinemia type I is nitisinone that inhibits 4-hydroxyphenyl pyruvic dioxygenase in competitive manner. In the present study, we have desig...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Biomedical Informatics
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498779/ https://www.ncbi.nlm.nih.gov/pubmed/28690379 http://dx.doi.org/10.6026/97320630013140 |